Result of General Meeting
Renalytix plc announced that all resolutions were passed at its General Meeting, with Resolution 1 receiving 99.86% in favour and Resolution 2 receiving 99.77% in favour. This outcome supports the company's recent capital raise, which has strengthened its balance sheet and eliminated convertible debt, positioning Renalytix to execute its commercial plans. Admission of 7,500,000 Second Tranche Placing Shares, 52,792,950 Subscription Shares, and 6,335,707 Retail Offer Shares is expected on 29 September 2026, bringing the total issued share capital to 670,459,333 Ordinary Shares.
Select text to share a quote on X · sign in to keep highlights & notes in your RENX notes
LONDON and NEW YORK, 28 September 2026 – Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focused on kidney disease, announces that at the General Meeting (“GM”) held earlier today, all resolutions were passed. Further details of each of the resolutions are set out in the Circular that contains the Notice of General Meeting, which was sent to the Company’s shareholders on 8 September 2026.
The results of the GM are detailed below:
| In favour | Against | Withheld | |||
|---|---|---|---|---|---|
| Resolution | Votes | % | Votes | % | Votes |
| 1 | 369,271,285 | 99.86 | 511,888 | 0.14 | 27,682 |
| 2 | 368,948,416 | 99.77 | 833,907 | 0.23 | 28,532 |
James McCullough, CEO of Renalytix, commented:
“I would like to thank our existing and new shareholders for their strong support of the Company through the recently completed capital raise. With the financing now complete and a significantly strengthened balance sheet, including eliminating all convertible debt, we are well positioned to execute on our commercial plans. We look forward to providing further updates on our progress in the coming months.”
Admission and Total Voting Rights
Application has been made to the London Stock Exchange for the admission to trading on AIM for the 7,500,000 Second Tranche Placing Shares, the 52,792,950 Subscription Shares and the 6,335,707 Retail Offer Shares (the ‘Second Tranche Shares’) ('Admission'). It is expected that Admission of the Second Tranche Shares will become effective and that trading will commence in the Second Tranche Shares at 8.00 a.m. on 29 September 2026. The Second Tranche Shares will rank pari passu with the Company's existing Ordinary Shares.
Following Admission, the total issued share capital of the Company will consist of 670,459,333 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of voting rights in the Company will be 670,459,333 and this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
Capitalised terms not defined have the same meaning as given to them in the Company's Circular dated 8 September 2026.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.